Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates
- Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of ...
Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110
CAMBRIDGE, Mass., July 21, 2025 ( GLOBE NEWSWIRE ) -- Korro Bio, Inc. ( Korro ) ( Nasdaq: KRRO ) , a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that it has been ...
Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday - Genpact ( NYSE:G ) , Coherent ( NYSE:COHR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Rosenblatt raised Coherent Corp. COHR price target from $80 to $95. Rosenblatt analyst Mike Genovese ...
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Korro Bio ( NASDAQ:KRRO ) , CG Oncology ( NASDAQ:CGON )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Korro Reports Full Year 2024 Financial Results and Provides Business Updates
CAMBRIDGE, Mass., March 18, 2025 ( GLOBE NEWSWIRE ) -- Korro Bio, Inc. ( Korro ) ( Nasdaq: KRRO ) , a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported full-year 2024 ...
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
CAMBRIDGE, Mass., March 14, 2025 ( GLOBE NEWSWIRE ) -- Korro Bio, Inc. ( Korro ) ( Nasdaq: KRRO ) , a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that the U.S.
Korro to Present at the TD Cowen 45th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 26, 2025 ( GLOBE NEWSWIRE ) -- Korro Bio, Inc. ( Korro ) ( Nasdaq: KRRO ) , a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, ...
Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 07, 2025 ( GLOBE NEWSWIRE ) -- Korro Bio, Inc. ( Korro ) ( Nasdaq: KRRO ) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, ...
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study ( REWRITE ) of KRRO-110 for Alpha-1 Antitrypsin Deficiency
-REWRITE study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of ...
This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - TechnipFMC ( NYSE:FTI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Citigroup analyst Atif Malik initiated coverage on Astera Labs, Inc.
WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data
Wave Life Sciences' stock soars on positive initial data showing the first-ever therapeutic RNA editing in humans in the phase Ib/IIa study of WVE-006 for AATD.
United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday - United Airlines Holdings ( NASDAQ:UAL )
U.S. stocks were mixed, with the Dow Jones index gaining around 100 points on Wednesday. Shares of United Airlines Holdings, Inc. UAL rose sharply during Tuesday's session following better-than-expected quarterly earnings.
Wall Street Analysts Think Korro Bio, Inc. ( KRRO ) Could Surge 239.54%: Read This Before Placing a Bet
The consensus price target hints at a 239.5% upside potential for Korro Bio, Inc. (KRRO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society
CAMBRIDGE, Mass., Sept. 30, 2024 ( GLOBE NEWSWIRE ) -- Korro Bio, Inc. ( Korro ) ( Nasdaq: KRRO ) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced one oral and two poster ...
Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society - Korro Bio ( NASDAQ:KRRO )
CAMBRIDGE, Mass., Sept. 30, 2024 ( GLOBE NEWSWIRE ) -- Korro Bio, Inc. ( Korro ) KRRO a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced one oral and two poster presentations at the ...
3 Stocks That Could Rise on European Bank Interest Rate Cuts - Broadcom ( NASDAQ:AVGO ) , ASML Holding ( NASDAQ:ASML )
U.S. stocks reacted positively following the Federal Open Market Committee's announcement in mid-September that it would lower interest rates by 50 basis points, wider than many analysts had anticipated.
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
The thrust of the company's long-term strategy is becoming clearer.
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
The healthcare company's pivot into a new set of technologies will have many implications for the stock.
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
This strategic play will take time to pay off, but it could keep growth going.
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications - Novo Nordisk ( NYSE:NVO )
Wednesday, Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S NVO to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases.
Gold Edges Lower; US Homebuilder Sentiment Rises For September - Tupperware Brands ( NYSE:TUP )
U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining around 0.2% on Tuesday. The Dow traded up 0.01% to 41,628.39 while the NASDAQ rose 0.19% to 17,624.93. The S&P 500 also rose, gaining, 0.03% to 5,634.76. Energy shares jumped by 1.3% on Tuesday.
Crude Oil Gains Over 1%; US Business Inventories Increase In July - Korro Bio ( NASDAQ:KRRO )
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 100 points on Tuesday. The Dow traded up 0.26% to 41,728.28 while the NASDAQ rose 0.73% to 17,721.04. The S&P 500 also rose, gaining, 0.39% to 5,655.10. Consumer discretionary shares jumped by 1.6% on Tuesday.
Korro to Participate in Upcoming Investor Conferences - Korro Bio ( NASDAQ:KRRO )
CAMBRIDGE, Mass., Sept. 10, 2024 ( GLOBE NEWSWIRE ) -- Korro Bio, Inc. ( Korro ) KRRO a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate ...
Korro to Participate in Upcoming September Investor and Scientific Conferences
CAMBRIDGE, Mass., Aug. 27, 2024 ( GLOBE NEWSWIRE ) -- Korro Bio, Inc. ( Korro ) ( Nasdaq: KRRO ) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will ...
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating - Korro Bio ( NASDAQ:KRRO )
William Blair initiated coverage on Korro Bio Inc. KRRO, a private RNA editing company that went public via a reverse merger with Frequency Therapeutics Inc. in an all-stock merger transaction.
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
NEW YORK, June 27, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) ( NASDAQ: TRML ) , a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced ...
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference
CAMBRIDGE, Mass., May 20, 2024 ( GLOBE NEWSWIRE ) -- Korro Bio, Inc. ( Korro ) ( Nasdaq: KRRO ) , a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, is presenting new preclinical data demonstrating the specificity and ...
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference - Korro Bio ( NASDAQ:KRRO )
KRRO-110 showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin ( AAT ) protein levels to greater than 60uM at week 13 in an in vivo genetic Alpha-1 Antitrypsin Deficiency ( AATD ) mouse model
Korro Announces $70 Million Private Placement
CAMBRIDGE, Mass., April 18, 2024 ( GLOBE NEWSWIRE ) -- Korro Bio, Inc. ( Korro ) ( Nasdaq: KRRO ) , a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that it has entered into a ...
Wall Street Analysts Believe Korro Bio, Inc. ( KRRO ) Could Rally 86.94%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 86.9% in Korro Bio, Inc. (KRRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Best Momentum Stocks to Buy for February 16th
Teaser: ECL, CDNS and KRRO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 16, 2023.
New Strong Buy Stocks for February 16th
CDNS, ECL, FMX, KRRO and RMR have been added to the Zacks Rank #1 (Strong Buy) List on February 16, 2024.
Ecolab Posts Strong Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Tuesday - Bruker ( NASDAQ:BRKR ) , Aspen Aerogels ( NYSE:ASPN )
U.S. stocks were lower, with the Dow Jones index dipping more than 500 points on Tuesday. Shares of Ecolab Inc. ECL rose during Tuesday's session after the company reported better-than-expected fourth-quarter financial results and issued first-quarter adjusted EPS guidance above estimates.
Does Korro Bio, Inc. ( KRRO ) Have the Potential to Rally 59.66% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 59.7% in Korro Bio, Inc. (KRRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency ( AATD ) and Progress Across its RNA Editing Portfolio - Korro Bio ( NASDAQ:KRRO )
KRRO-110 has a potentially best-in-class profile with secretion of ~50µM functional AAT protein after a single dose in a preclinical mouse model Evidence of greater than 40% editing of SERPINA1 RNA in non-human primates ( NHPs ) further supports the potential translation of KRRO-110 in humans
Why Newly Listed Korro Bio ( KRRO ) Shares Are Gaining Today - Korro Bio ( NASDAQ:KRRO )
H.C. Wainwright initiated coverage on Korro Bio Inc KRRO, a biotech company developing genetic medicines focused on editing ribonucleic acid ( RNA ) to treat various diseases. Recently, Korro Bio went public via a reverse merger with Frequency Therapeutics Inc. in an all-stock merger ...
These 3 Biotech Stocks More Than Doubled in November. Can They Fly Even Higher in 2024?
These stocks are coming off a banner month, but what about the road ahead?
Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023 - Codexis ( NASDAQ:CDXS )
REDWOOD CITY, Calif., Nov. 28, 2023 ( GLOBE NEWSWIRE ) -- Codexis, Inc.
Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023
REDWOOD CITY, Calif., Nov. 28, 2023 ( GLOBE NEWSWIRE ) -- Codexis, Inc. ( NASDAQ: CDXS ) , a leading enzyme engineering company, today announced it will host a virtual key opinion leader ( KOL ) event focused on its Enzyme-Catalyzed Oligonucleotide ( ECO ) Synthesis™ platform and the broader RNA ...
Korro Bio Appoints Dr. Rachel Meyers to Board of Directors - Korro Bio ( NASDAQ:KRRO )
Biotech veteran brings more than two decades of life science experience to Korro's Board
Chegg, Perdoceo Education And Other Big Stocks Moving Lower On Monday - ReAlpha Tech Corp ( NASDAQ:AIRE ) , Chegg ( NYSE:CHGG )
U.S. stocks traded higher, with the Dow Jones gaining over 50 points on Monday. Here are some big stocks recording losses in today's session. Yatsen Holding Limited YSG shares tumbled 24.2% to $0.6559. Yatsen Holding is expected to release its unaudited financial results for the third quarter on ...
